Literature DB >> 21327531

Prognostic factors for post-recurrence survival in esophageal squamous cell carcinoma patients with recurrence after resection.

Po-Kuei Hsu1, Bing-Yen Wang, Chien-Sheng Huang, Yu-Chung Wu, Wen-Hu Hsu.   

Abstract

OBJECTIVE: The survival of recurrent esophageal cancer is poor. But reports regarding prognostic factors for post-recurrence survival are limited. We analyzed the recurrence pattern and the prognostic factors for post-recurrence survival in esophageal squamous cell carcinoma with recurrence after resection.
METHODS: Two hundred sixty-eight patients were included. Tumor recurrence occurred in 115 (42.9%) patients. Recurrence pattern was classified as locoregional, distant, and combined recurrence. The post-recurrence survival was defined as the interval between initial recurrence and either death or the last follow-up.
RESULTS: Mediastinum lymphadenopathy was the most common site for locoregional recurrence, whereas lung, liver, and bone were the most common sites for distant recurrence. The overall 1- and 2-year post-recurrence survival rates were 32.6% and 12.6% with a median survival after recurrence of 6.0 months. The independent prognostic factors included liver recurrence (HR = 2.255, 95%CI = 1.073-4.741, p = 0.032), time to recurrence ≤10 months (HR = 2.657, 95%CI = 1.438-4.911, p = 0.002), and no treatment for recurrences (HR = 2.745, 95%CI = 1.635-4.608, p < 0.001).
CONCLUSIONS: We identify liver recurrence, early recurrence, and no treatment for recurrence as risk factors for dismal post-recurrence survival.

Entities:  

Mesh:

Year:  2011        PMID: 21327531     DOI: 10.1007/s11605-011-1458-1

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  19 in total

Review 1.  Neoadjuvant treatment of esophageal cancer.

Authors:  Nicholas P Campbell; Victoria M Villaflor
Journal:  World J Gastroenterol       Date:  2010-08-14       Impact factor: 5.742

2.  Prognostic factors and patterns of recurrence in esophageal cancer assert arguments for extended two-field transthoracic esophagectomy.

Authors:  Justin K Smit; Bareld B Pultrum; Hendrik M van Dullemen; Gooitzen M Van Dam; Henk Groen; John T M Plukker
Journal:  Am J Surg       Date:  2010-04-20       Impact factor: 2.565

3.  Pattern of recurrence after oesophageal resection for cancer: clinical implications.

Authors:  S Y Law; M Fok; J Wong
Journal:  Br J Surg       Date:  1996-01       Impact factor: 6.939

4.  Pattern of recurrence after extended radical esophagectomy with three-field lymph node dissection for squamous cell carcinoma in the thoracic esophagus.

Authors:  M S Bhansali; H Fujita; T Kakegawa; H Yamana; T Ono; S Hikita; Y Toh; T Fujii; U Tou; K Shirouzu
Journal:  World J Surg       Date:  1997 Mar-Apr       Impact factor: 3.352

5.  The recurrence pattern of esophageal carcinoma after transhiatal resection.

Authors:  J B Hulscher; J W van Sandick; J G Tijssen; H Obertop; J J van Lanschot
Journal:  J Am Coll Surg       Date:  2000-08       Impact factor: 6.113

6.  Association of the primary tumor location with the site of tumor recurrence after curative resection of thoracic esophageal carcinoma.

Authors:  Yuichiro Doki; Osamu Ishikawa; Ko Takachi; Isao Miyashiro; Yo Sasaki; Hiroaki Ohigashi; Kohei Murata; Terumasa Yamada; Shingo Noura; Hidetoshi Eguchi; Toshiyuki Kabuto; Shingi Imaoka
Journal:  World J Surg       Date:  2005-06       Impact factor: 3.352

7.  Tumor self-seeding by circulating cancer cells.

Authors:  Mi-Young Kim; Thordur Oskarsson; Swarnali Acharyya; Don X Nguyen; Xiang H-F Zhang; Larry Norton; Joan Massagué
Journal:  Cell       Date:  2009-12-24       Impact factor: 41.582

8.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

9.  Prognostic factors after oesophagectomy and extended lymphadenectomy for squamous oesophageal cancer.

Authors:  H Osugi; M Takemura; N Takada; K Hirohashi; H Kinoshita; M Higashino
Journal:  Br J Surg       Date:  2002-07       Impact factor: 6.939

10.  Treatment response and prognosis of patients after recurrence of esophageal cancer.

Authors:  Hideaki Shimada; Hiroyuki Kitabayashi; Yoshihiro Nabeya; Shin-ichi Okazumi; Hisahiro Matsubara; Yutaka Funami; Yukimasa Miyazawa; Tooru Shiratori; Takashi Uno; Hisao Itoh; Takenori Ochiai
Journal:  Surgery       Date:  2003-01       Impact factor: 3.982

View more
  29 in total

1.  Hospital type- and volume-outcome relationships in esophageal cancer patients receiving non-surgical treatments.

Authors:  Po-Kuei Hsu; Hui-Shan Chen; Bing-Yen Wang; Shiao-Chi Wu; Chao-Yu Liu; Chih-Hsun Shih; Chia-Chuan Liu
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

2.  Prognostic factors in patients with recurrence after complete resection of esophageal squamous cell carcinoma.

Authors:  Xiao-Dong Su; Dong-Kun Zhang; Xu Zhang; Peng Lin; Hao Long; Tie-Hua Rong
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

3.  Combined treatment with anlotinib and chemotherapy for advanced esophageal squamous cell carcinoma improved patient survival: a case report.

Authors:  Dongyang Yang; Fei Xu; Xiaorong Lai; Ying Li; Huibing Gao; Ying Xu; Rongrong Chen; Dong Ma
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

4.  Pattern of postoperative recurrence and hepatic and/or pulmonary resection for liver and/or lung metastases from esophageal carcinoma.

Authors:  Hirofumi Ichida; Hiroshi Imamura; Jiro Yoshimoto; Hiroyuki Sugo; Yoshiaki Kajiyama; Masahiko Tsurumaru; Kenji Suzuki; Yoichi Ishizaki; Seiji Kawasaki
Journal:  World J Surg       Date:  2013-02       Impact factor: 3.352

5.  Treatment Outcomes and Prognostic Factors After Recurrence of Esophageal Squamous Cell carcinoma.

Authors:  Yoichi Hamai; Jun Hihara; Manabu Emi; Takaoki Furukawa; Yuta Ibuki; Ichiko Yamakita; Tomoaki Kurokawa; Morihito Okada
Journal:  World J Surg       Date:  2018-07       Impact factor: 3.352

6.  Comparison of survival among neoadjuvant chemoradiation responders, non-responders and patients receiving primary resection for locally advanced oesophageal squamous cell carcinoma: does neoadjuvant chemoradiation benefit all?

Authors:  Po-Kuei Hsu; Ling-I Chien; Chien-Sheng Huang; Chih-Cheng Hsieh; Yu-Chung Wu; Wen-Hu Hsu; Teh-Ying Chou
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-05-31

7.  Open versus thoracoscopic esophagectomy in patients with esophageal squamous cell carcinoma.

Authors:  Po-Kuei Hsu; Chien-Sheng Huang; Yu-Chung Wu; Teh-Ying Chou; Wen-Hu Hsu
Journal:  World J Surg       Date:  2014-02       Impact factor: 3.352

8.  Weekly Chemotherapy of 5-Fluorouracil plus Cisplatin Concurrent with Radiotherapy for Esophageal Squamous Cell Carcinoma Patients with Postoperative Locoregional Recurrence: Results from a Phase II Study.

Authors:  Baoqing Chen; Qiwen Li; Qiaoqiao Li; Bo Qiu; Mian Xi; Mengzhong Liu; Yonghong Hu; Yujia Zhu
Journal:  Oncologist       Date:  2019-12-27

9.  Postoperative Radiotherapy in Pathological T2-3N0M0 Thoracic Esophageal Squamous Cell Carcinoma: Interim Report of a Prospective, Phase III, Randomized Controlled Study.

Authors:  Wei Deng; Jinsong Yang; Wenjie Ni; Chen Li; Xiao Chang; Weiming Han; Zongmei Zhou; Dongfu Chen; Qinfu Feng; Jun Liang; Jima Lv; Xiaozhen Wang; Xin Wang; Lei Deng; Wenqing Wang; Nan Bi; Tao Zhang; Yexiong Li; Shugeng Gao; Qi Xue; Yousheng Mao; Kelin Sun; Xiangyang Liu; Dekang Fang; Dali Wang; Jian Li; Jun Zhao; Kang Shao; Zhishan Li; Xinjie Chen; Lei Han; Lifang Wang; Jie He; Zefen Xiao
Journal:  Oncologist       Date:  2020-02-21

10.  Postoperative Adjuvant Therapy Versus Surgery Alone for Stage IIB-III Esophageal Squamous Cell Carcinoma: A Phase III Randomized Controlled Trial.

Authors:  Wenjie Ni; Shufei Yu; Zefen Xiao; Zongmei Zhou; Dongfu Chen; Qinfu Feng; Jun Liang; Jima Lv; Shugeng Gao; Yousheng Mao; Qi Xue; Kelin Sun; Xiangyang Liu; Dekang Fang; Jian Li; Dali Wang; Jun Zhao; Yushun Gao
Journal:  Oncologist       Date:  2021-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.